Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

An Ecological Momentary Intervention for the Reduction of Impairment in Somatic Symptom Disorder

9 juin 2026 mis à jour par: Urs Nater, University of Vienna

Persistent somatic symptoms significantly impair the daily lives of individuals with Somatic Symptom Disorder (SSD). Negative psychological factors (NPFs), such as catastrophizing and negative affectivity, further compound this impairment. Yet, few studies have examined strategies in daily life that directly target somatic symptoms and their dynamic relationship with NPFs. The goal of this clinical trial is to investigate if an Ecological Momentary Intervention (EMI) using music listening and cognitive reappraisal can reduce the intensity of and impairment due to somatic symptoms in 40 individuals with Somatic Symptom Disorder (SSD), aged 18-65 years.

Participants will report symptom intensity, impairment, and NPFs up to four times daily via a smartphone app over a six-week period. Using an intraindividual randomized controlled design, during weeks two to five, participants will be randomly assigned in the ratio of 50:25:25 to no intervention, music listening, and cognitive reappraisal, both at fixed times (evening measurement) and during episodes of acute somatic impairment.

Aperçu de l'étude

Description détaillée

Somatic symptoms, particularly when medically unexplained, are common stress-related health issues that significantly affect the daily lives of those experiencing them, especially in the more severe form known as Somatic Symptom Disorder (SSD). Specific negative psychological factors (NPFs), such as catastrophizing, negative affectivity, and rumination about somatic symptoms, may contribute to the intensity of and impairment caused by somatic symptoms (Mewes et al., 2022). The intensity and impairment associated with somatic symptoms are crucial outcome variables for both clinicians and those affected, and should therefore be considered in intervention studies (Rief et al., 2017). The best psychological treatment for somatic symptoms is cognitive behavioral therapy with low to moderate effect sizes (van Dessel et al., 2014). Considering the long waiting time for a therapy appointment and the small effect size, other interventions should be considered. Ecological Momentary Interventions (EMIs; Heron & Smyth, 2010; Mewes, 2022) provide a promising approach for delivering interventions in real time, directly in people's daily lives and their natural environment. By collecting real-time data, EMIs can provide insights into the dynamic relationship between NPFs and somatic symptoms that would otherwise go unnoticed. Because they can address specific events as they occur, EMIs also enable just-in-time interventions in daily life. In addition, real-time assessment of treatment outcomes can contribute to the evaluation of effective interventions. Music listening could be such an intervention. Music listening plays an important role in pain management (Frei & Szucs, 2025) as listening to music in accordance with the individual music preference has an analgesic effect on pain (Van der Valk Bouman et al., 2024). Music that is perceived as happy predicts the reduction of intensity and impairment caused by somatic symptoms in people with SSD (Feneberg et al., 2021). Thus, music listening seems to be a promising low-threshold intervention in daily life. Another promising approach to reduce somatic symptoms is cognitive reappraisal, since people with SSD show significantly less use of cognitive reappraisal than healthy individuals (Schnabel et al., 2022). When cognitive reappraisal is used as a standalone intervention, it reduces symptom annoyance in individuals with medically unexplained somatic symptoms (Kleinstäuber et al., 2019). Furthermore, when combined with other Cognitive Behavioral Therapy interventions such as stress management, it leads to an improvement in the impairment caused by somatic symptoms (Allen et al., 2006; Visser & Bouman, 2001). The present study will examine the effects of an EMI in individuals with SSD, employing an intraindividual randomized controlled design with repeated measures. The investigators hypothesize that, from baseline (week 1) to post-intervention (week 6), participants will show a reduction in the weekly average intensity of somatic symptoms, a reduction in impairment due to somatic symptoms, and a reduction in the strength of negative psychological factors (intermediate effect). Furthermore, the investigators hypothesize that, following an acute event, impairment due to somatic symptoms, the intensity of somatic symptoms, and the severity of negative psychological factors will decrease more during an intervention event than during a control event (immediate effects). In addition, the investigators expect a decrease in somatic symptom severity as measured by the Patient Health Questionnaire-15, a decrease in symptom-related distress as measured by the Somatic Symptom Disorder - B Criteria Scale, and a change in perceived stress as measured by the Perceived Stress Scale -10 from pre-intervention (before week 1) to post-intervention (after week 6). Finally, the investigators hypothesize that higher expectations regarding future somatic symptom intensity will be associated with higher somatic symptom intensity at the subsequent assessment, and that higher expectations regarding future somatic symptom impairment will be associated with higher somatic symptom intensity at the subsequent assessment (fixed measurement points throughout the day). Potential participants will be recruited through flyers, online announcements, and potentially newspaper advertisements. The participants will be German-speaking individuals with SSD. Participants will be screened for SSD using a semi-structured interview based on the DSM-5, an operationalization used in a previous study (Mewes et al., 2022). The sample size was calculated using G*Power (Faul et al., 2007) for an F-test in a repeated-measures ANOVA with the within factors. The main outcome is a change in somatic symptoms, with an estimated effect size of f = 0.35 based on Kleinstäuber (2011), and an assumed correlation among repeated measures of 0.3. With a desired power of 0.90, an alpha error of 0.05, one group, two measurement points (average impairment levels baseline vs. post-intervention), and a nonsphericity correction of 1, the required total sample size was 33 participants. To ensure robustness and improve generalizability, and considering a dropout rate of 20%, the aim is to include 40 participants. Potential study participants will either undergo an initial online screening, during which they will be informed about the study and then contacted by us via phone, or proceed directly to a phone screening. During this call, information about the study will be provided, and a semi-structured interview to check for SSD will be conducted (Mewes et al., 2022). Upon receiving verbal consent to participate in the study, an appointment for the distribution of study materials will be arranged. If participants give their verbal consent during the phone screening, they can complete questionnaires, including potential control variables, before the distribution appointment. A link to the pre-questionnaire on SoSci Survey (Leiner, 2024) will be sent via email. If consent is not given during the phone screening, these questionnaires will be completed at the distribution appointment after consent is obtained. At the distribution appointment, the study information will first be discussed with the participants, and written consent to participate in the study will be obtained. Additionally, study materials (either a study smartphone or the installation of an app on the participants' smartphones) and a study manual will be distributed. The EMI begins one day after material distribution. After the post phase of the EMI, participants will again complete questionnaires on SoSci Survey (Leiner, 2024) regarding somatic symptoms. A return date for the materials will be scheduled via email. At the return appointment after the study period, all study materials will be collected. To achieve the research objective, an intraindividual randomized controlled trial will be conducted. An EMI will be conducted, which will be administered using the software MovisensXS. The study consists of three phases spanning a total of 42 days: The baseline phase (7 days), the intervention phase (28 days), and the post phase (7 days). During all three phases, data will be collected three times a day (11 am, 4 pm, and a self-initiated evening assessment). Additionally, in the intervention phase, an additional measurement point occurs 20 minutes after the evening assessment. During all three phases, participants receive prompts through the app at 11 am and 4 pm. The evening assessment can be initiated before going to bed by pressing a button in the app; participants will also receive a reminder at 9 pm. Additionally, participants will be asked to make self-initiated event-based inputs by pressing a button in the app whenever they feel acute somatic symptoms. They will then receive event-related questions immediately and 20 minutes later via a prompt. During the intervention phase, participants will be randomly assigned each day to either an intervention event or a control event. The intervention takes place in the evening and after self-initiated measurements, which are carried out due to impairment caused by somatic symptoms. On any given day, participants will have a 50% chance of receiving no intervention, and a 25% chance of receiving either music listening (Intervention 1) or cognitive reappraisal (Intervention 2). On days allocated to the intervention event, after the evening measurement, participants will engage in a fixed exercise session and receive another prompt 20 minutes after. In the control event, there will be no exercise between the measurement time points. In addition, at the event-based measurements, participants will again be randomly assigned in a 50:25:25 ratio to either continue with their current activity (control condition), engage in music listening (Intervention 1), or perform a cognitive reappraisal task of their somatic symptoms (Intervention 2).

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • State of Vienna
      • Vienna, State of Vienna, L'Autriche, 1010
        • Recrutement
        • University of Vienna
        • Contact:
        • Sous-enquêteur:
          • Nadja Plumbaum, MSc.

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Somatic Symptom Disorder

Exclusion Criteria:

  • chronic physical illnesses that fully explain the somatic symptoms
  • current psychotic disorder
  • current bipolar disorder
  • current self-harming behavior
  • current suicidality
  • current psychotherapy
  • alcohol, drug, or medication dependence within the past 6 months

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Music listening/Cognitive reappraisal vs. no intervention

Intervention (music listening, cognitive reappraisal) vs. no intervention Every participant will be randomly assigned (25:25:50) to one of the following conditions after they feel more impaired by their somatic symptoms than usual or after the evening measurement:

  1. Music listening: listening to self-selected music perceived as happy for 10 minutes (intervention condition)
  2. Cognitive reappraisal: (intervention condition)
  3. No intervention. Participants continue with their previous task, but without music listening (control condition).
Participants listen to self-selected happy music based on Feneberg et al. (2021). The duration is 10 minutes.
Participants will be asked to write down their thoughts regarding their somatic complaints. They will be asked to consider the complaints from a more positive perspective. Subsequently, participants reread their written complaints. To develop another point of view, participants will be encouraged to apply more helpful thoughts to their somatic symptoms, such as "I feel really bad right now, but I'm certain I do not have a serious illness." (Kleinstäuber et al., 2019) The intervention lasts between 5 - 10 minutes.
Participants continue with their previous task, but without music listening

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in intermediate Intensity of and impairment by somatic symptoms and in the strength of negative psychological factors
Délai: baseline (week 1) to post (week 6)
Intensity of somatic symptoms: visual analog scale (0-100; higher scores indicate a greater level of intensity), impairment by somatic symptoms visual analog scale (0-100; higher scores indicate a greater level of impairment), negative psychological factors: 5-point Likert scale; higher levels indicate stronger negative psychological factors.
baseline (week 1) to post (week 6)
Change in short-term impairment due to somatic symptoms
Délai: T0: directly after an event of acute impairment due to somatic symptoms; T1: 20 minutes after T0
Impairment due to somatic symptoms (visual analog scale, 0-100, higher scores indicate greater impairment).
T0: directly after an event of acute impairment due to somatic symptoms; T1: 20 minutes after T0
Change in short-term intensity of somatic symptoms
Délai: T0: directly after an event of acute impairment due to somatic symptoms; T1: 20 minutes after T0
Intensity due to somatic symptoms (visual analog scale, 0-100; higher scores indicate greater intensity)
T0: directly after an event of acute impairment due to somatic symptoms; T1: 20 minutes after T0
Change in short-term severity of negative psychological factors
Délai: T0: directly after an event of acute impairment due to somatic symptoms. T1: 20 minutes after T0
Negative psychological factors (5-point Likert scale).
T0: directly after an event of acute impairment due to somatic symptoms. T1: 20 minutes after T0

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in somatic symptom severity measured with the Patient Health Questionnaire-15
Délai: pre (before week 1) to post (after week 6)
Somatic Symptom Severity (Patient Health Questionnaire-15): Values range from 0-30; Higher scores indicate a greater somatic symptom severity.
pre (before week 1) to post (after week 6)
Change in symptom-related distress measured with the Somatic Symptom Disorder-B Criteria Scale
Délai: Pre (before week 1) -Post (after week 6)
Symptom-related distress: Somatic Symptom Disorder-B Criteria Scale. The values range from 0 to 48. Higher scores indicate more symptom-related distress.
Pre (before week 1) -Post (after week 6)
Change in perceived stress measured with the Perceived Stress Scale 10
Délai: pre (before week 1) - post (after week 6)
Perceived stress (Perceived Stress Scale 10). The value ranges from 0 to 40; Higher scores indicate more perceived stress.
pre (before week 1) - post (after week 6)
Change of expectations regarding intensity of somatic symptoms
Délai: fixed measurement points morning - day - evening
Expectations regarding future somatic symptom intensity (visual analog scale; 0-100)
fixed measurement points morning - day - evening
Change of expectations regarding impairment due to somatic symptoms
Délai: fixed measurement time points morning - day - evening
Expectations regarding future somatic symptom impairment: visual analog scale (0-100)
fixed measurement time points morning - day - evening

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change in the illness perception measured with the Brief Illness Perception Questionnaire
Délai: pre (before week 1) - post (after week 6)
Illness perception (Brief Illness Perception Questionnaire). Values range from 0 to 80. Higher scores indicate a worse illness perception.
pre (before week 1) - post (after week 6)
Change in Emotion regulation measured with the Emotion Regulation Questionnaire
Délai: pre (before week 1) - post (after week 6)
Emotion Regulation Questionnaire. Values range from 1 to 7 per item. Higher scores in the subscales indicate more use of this strategy
pre (before week 1) - post (after week 6)
Change in somatic symptom amplification measured with the Somatosensory Amplification Scale
Délai: pre (before week 1) - post (after week 6)
Somatosensory Amplification Scale (SSAS): Values range from 10 to 50. Higher scores indicate more somatosensory amplification.
pre (before week 1) - post (after week 6)
Change in symptom-related disability measured with the Pain Disability Index-adapted
Délai: pre (before week 1) - post (after week 6)
Pain Disability Index-adapted (PDI): Values range from 0 to 70. Higher scores indicate pain is interfering more with daily life.
pre (before week 1) - post (after week 6)
Change in the health-related quality of life measured with the Short Form Health Survey 12
Délai: pre (before week 1) - post (after week 6)
Short Form Health Survey-12 (SF-12): Values range from 0 to 100. Higher scores indicate better self-reported health.
pre (before week 1) - post (after week 6)
Change in depression measured with the Patient Health Questionnaire-9
Délai: pre (before week 1) - post (after week 6)
Patient Health Questionnaire-9 (PHQ-9): Values range from 0 to 27. Higher scores indicate worse depression symptoms.
pre (before week 1) - post (after week 6)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Ricarda Nater-Mewes, Prof., University of Klagenfurt
  • Chercheur principal: Urs M. Nater, Prof., University of Vienna

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 juin 2025

Achèvement primaire (Estimé)

1 octobre 2026

Achèvement de l'étude (Estimé)

1 octobre 2026

Dates d'inscription aux études

Première soumission

21 mai 2026

Première soumission répondant aux critères de contrôle qualité

9 juin 2026

Première publication (Réel)

12 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner